Outcomes in diabetic vs nondiabetic patients requiring cardiac resynchronization therapy for heart failure: A
Aman Goyal1,2, Muhammad Daoud Tariq3, Abdul Moiz Khan4
1Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India.
Background:
Heart failure (HF) affects millions globally, causing severe symptoms and poor prognosis. Cardiac resynchronization therapy (CRT) has been shown to improve heart function and quality of life in HF patients with electrical dyssynchrony, but its effectiveness in diabetic patients remains unclear due to the complexities associated with diabetes.
Objective:
This study evaluates the impact of diabetes mellitus on CRT by comparing outcomes between diabetic and nondiabetic patients through a meta-analysis.
Methods:
A comprehensive literature search identified studies on CRT in HF patients both with and without diabetes mellitus. Pooled risk ratios (RRs) and mean differences were calculated using a random-effects model with 95% confidence intervals and statistical significance set at P < .05.
Results:
Analysis of 13 observational studies involving 20,073 participants revealed that diabetic patients had a significantly increased risk of all-cause mortality (RR 1.34, P < .00001) and cardiovascular death (RR 1.49, P = .002) compared with nondiabetic patients. However, no statistically significant differences were observed between groups in the risk of stroke (RR 3.99, P = .05), myocardial infarction (RR 1.16, P = .30), changes in left ventricular (LV) ejection fraction (P = .22), LV end-systolic volume (P = .10), and LV end-diastolic volume (P = .63).
Conclusion:
These findings suggest that diabetic patients undergoing CRT face a higher risk of all-cause and cardiovascular mortality compared with nondiabetic patients. The increased mortality risk highlights the need for tailored treatment strategies, emphasizing the judicious use of CRT in diabetic patients.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care
Heart Failure Drugs: Inotropic Agents


